Vaxcyte’s 31-valent vaccine hits primary endpoints, sending shares up 57%
Vaxcyte reported positive phase 3 results for its 31-valent pneumococcal vaccine, VAX-31, demonstrating non-inferiority against Pfizer and Merck competitors. The stock surged 57% in pre-market trading, reaching $88.50, as the company prepares for an FDA approval application in early 2028.